Direct‐acting antiviral therapy for chronic hepatitis C virus genotype 4 infection: Exploring new regimens

The optimal antiviral regimen for hepatitis C virus (HCV) genotype 4 is still a subject of investigation. The report in this issue of Health Science Reports by Asselah and colleagues investigated the additional benefit of extending treatment duration of the ombitasvir/paritaprevir/ritonavir plus rib...

Descripción completa

Detalles Bibliográficos
Autor principal: Toyoda, Hidenori
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2019
Materias:
Perspective
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6427055/
https://www.ncbi.nlm.nih.gov/pubmed/30937390
http://dx.doi.org/10.1002/hsr2.106
_version_ 1783405128702754816
author Toyoda, Hidenori
author_facet Toyoda, Hidenori
author_sort Toyoda, Hidenori
collection PubMed
description The optimal antiviral regimen for hepatitis C virus (HCV) genotype 4 is still a subject of investigation. The report in this issue of Health Science Reports by Asselah and colleagues investigated the additional benefit of extending treatment duration of the ombitasvir/paritaprevir/ritonavir plus ribavirin regimen to up to 24 weeks for patients with HCV genotype 4 and compensated cirrhosis.
format Online
Article
Text
id pubmed-6427055
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-64270552019-04-01 Direct‐acting antiviral therapy for chronic hepatitis C virus genotype 4 infection: Exploring new regimens Toyoda, Hidenori Health Sci Rep Perspective The optimal antiviral regimen for hepatitis C virus (HCV) genotype 4 is still a subject of investigation. The report in this issue of Health Science Reports by Asselah and colleagues investigated the additional benefit of extending treatment duration of the ombitasvir/paritaprevir/ritonavir plus ribavirin regimen to up to 24 weeks for patients with HCV genotype 4 and compensated cirrhosis. John Wiley and Sons Inc. 2019-03-04 /pmc/articles/PMC6427055/ /pubmed/30937390 http://dx.doi.org/10.1002/hsr2.106 Text en © 2019 The Author. Health Science Reports published by Wiley Periodicals, Inc. This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.
spellingShingle Perspective
Toyoda, Hidenori
Direct‐acting antiviral therapy for chronic hepatitis C virus genotype 4 infection: Exploring new regimens
title Direct‐acting antiviral therapy for chronic hepatitis C virus genotype 4 infection: Exploring new regimens
title_full Direct‐acting antiviral therapy for chronic hepatitis C virus genotype 4 infection: Exploring new regimens
title_fullStr Direct‐acting antiviral therapy for chronic hepatitis C virus genotype 4 infection: Exploring new regimens
title_full_unstemmed Direct‐acting antiviral therapy for chronic hepatitis C virus genotype 4 infection: Exploring new regimens
title_short Direct‐acting antiviral therapy for chronic hepatitis C virus genotype 4 infection: Exploring new regimens
title_sort direct‐acting antiviral therapy for chronic hepatitis c virus genotype 4 infection: exploring new regimens
topic Perspective
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6427055/
https://www.ncbi.nlm.nih.gov/pubmed/30937390
http://dx.doi.org/10.1002/hsr2.106
work_keys_str_mv AT toyodahidenori directactingantiviraltherapyforchronichepatitiscvirusgenotype4infectionexploringnewregimens

Ejemplares similares